Skip to main content
. 2021 Apr 3;21:174. doi: 10.1186/s12903-021-01499-y

Table 2.

Use of Antibiotics and/or Analgesics and treatment by diagnosis

Diagnosis Patients n Pre-SARS-COV-2 Patients n During-SARS-COV-2
Antibiotics/Analgesics n(%) local treatment n(%) Antibiotics/Analgesics n (%) Local treatment n (%)
Group1 413 45 (10.9%) 364 (88.1%) 858 219 (25.5%) 583 (67.9%)
Group2 314 61 (19.4%) 259 (82.5%) 529 227 (44.9%) 367 (69.4%)
Group3 24 1 (4.2%) 7 (29.2%) 56 2 (3.6%) 10 (17.9%)
Group4 161 76 (47.2%) 132 (82.0%) 227 99 (43.6%) 156 (68.7%)
Group5 695 103 (14.8%) 655 (94.2%) 492 208 (42.3%) 474 (96.3%)
Group6 58 6 (6.1%) 31 (53.4%) 23 6 (26.1%) 7 (30.4%)
Group7 51 12 (23.5%) 37 (72.5%) 257 197 (76.7%) 39 (15.2%)

Group1: Acute Pulpitis (K04.0) and/or Acute apical periodontitis (K04.4)

Group2: Acute gingivitis (K05.0) and/or Acute pericoronitis (K05.2)

Group3: Temporomandibular joint disorders (K07.6)

Group4: Cellulitis and abscess of mouth (K12.2)

Group5: Open wound of lip and/or oral cavity (S01.5)

Group6: Fracture of tooth (S02.5)

Group7: Others (non-emergency diseases, including diagnoses related to prosthesis, aesthetic, recall or maintenance)